2014 Fiscal Year Final Research Report
The mechanism for multiple sclerosis-related pain and its new therapy
| Project/Area Number |
24590731
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pain science
|
|---|
| Research Institution | Tohoku Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAKURADA Shinobu 東北薬科大学, 薬学部, 教授 (30075816)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 多発性硬化症 / 疼痛 / μ受容体 / 鎮痛薬 |
|---|
| Outline of Final Research Achievements |
The narcotic analgesic oxycodone and κ-opioid receptor agonist nalfurafine are extremely effective against morphine-resistant multiple sclerosis-related pain. The effect of these analgesics against the multiple sclerosis-related pain may be partially mediated through the activation of κ-opioid receptors. In addition, the reduced analgesic effect of morphine against the multiple sclerosis-related pain may be caused by the desensitization of μ-opioid receptors that is revealed by the activation of NMDA receptors. In fact, the morphine analgesia reduced against the multiple sclerosis-related pain recovers by a single injection of NMDA receptor antagonists.
|
| Free Research Field |
神経科学
|
